Eli Lilly bets on Verve, cholesterol gene therapy in $1.3 billion deal

INDIANAPOLIS, Indiana: Eli Lilly is making a bold play in cardiovascular gene therapy, announcing plans to acquire its partner Verve Therapeutics for up to US$1.3 billion as it expands beyond its blockbuster diabetes and weight-loss drugs.
The move signals the pharmaceutical giant's more profound commitment to developing one-time gene-editing treatments for heart disease — specifically targeting high cholesterol — through technologies like base editing.
Under the agreement announced this week, Lilly will pay $10.5 per share for Verve, a 67.5 percent premium over the biotech's previous closing price. Verve shares surged 75 percent to $11.02 in early trading. The Financial Times was the first to report that the deal was in the works.
The transaction includes nearly $1 billion in upfront payments and up to $300 million in milestone-based payouts.
The companies had already been collaborating on experimental therapies that use gene editing to reduce cholesterol in patients with a history of cardiovascular issues — a significant focus area for Lilly as it seeks long-term growth.
Verve's leading candidate, VERVE-102, is in early trials and targets the PCSK9 gene, which is linked to cholesterol regulation. The therapy, based on base editing, aims to make a one-time change to a patient's DNA and is expected to be launched later this decade.
"We are skeptical about the true market need of additional genetic medicines in these indications," said BMO Capital Markets analyst Evan Seigerman ahead of the announcement, citing competition from other cholesterol-lowering drugs.
Still, industry observers said the deal is a significant boost for Verve and for the broader gene-editing field, which has struggled to attract investor enthusiasm recently.
"This keeps Lilly focused within the cardiometabolic space," said Kevin Gade, COO at Bahl & Gaynor, referring to Lilly's core strength areas like diabetes and weight loss. Its therapies Mounjaro and Zepbound are projected to bring in over $30 billion this year, according to LSEG.
Lilly has inked multiple partnerships with gene-editing firms in recent years, but this latest buyout is one of its boldest bets yet in the field.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Globe and Mail

an hour ago

• Globe and Mail

LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?

Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, strong market capitalization and global footprint. Both companies have a strong presence in immunology, oncology and neuroscience areas. Other than that, AbbVie also has products for aesthetics and eye care, while Lilly boasts a leading presence in cardiometabolic health. While AbbVie has seen tremendous success with its immunology drugs, Lilly's GLP-1 drugs, Mounjaro and Zepbound, under its cardiometabolic health business, are the key to its success story. Both stocks are being seen as defensive pharma plays amid tariff and pricing uncertainties. But which one is a better investment option today? Let's take a closer look at their fundamentals, growth prospects and challenges to make an informed choice. The Case for Lilly Lilly has a strong portfolio of medicines to treat diabetes and other cardiometabolic diseases, and its cardiometabolic business is its most successful business, particularly with the success of its popular tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. Despite being on the market for less than three years, GLP-1 medicines, Mounjaro and Zepbound, became key top-line drivers for Lilly, with demand rising rapidly. Mounjaro and Zepbound account for around 50% of the company's total revenues. Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first quarter of 2025, driven by launches of the drugs in new international markets and improved supply from ramped-up production. We believe that increased uptake in outside U.S. markets and deeper penetration in the U.S. market will continue to drive Mounjaro and Zepbound's growth in future quarters. Approvals for new indications can also drive sales of Mounjaro and Zepbound higher. Other than Mounjaro and Zepbound, Lilly has gained approvals for some other new drugs in the past couple of years across different therapeutic areas like Omvoh, Jaypirca, Ebglyss and Kisunla (donanemab). Lilly expects its new drugs, Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025. Lilly is also making rapid pipeline progress in obesity, diabetes and cancer, with several key mid and late-stage data-readouts expected this year. Lilly is investing broadly in obesity and has several next-gen candidates currently in clinical development. Lilly has its share of problems. Prices of most of Lilly's products are declining in the United States. In 2025, Lilly expects a mid-to-high single-digit percentage price decline, including U.S. Part D changes. Potential competition in the GLP-1 diabetes/obesity market is another headwind. Mounjaro and Zepbound face strong competition from Novo Nordisk 's NVO semaglutide medicines, Ozempic for diabetes and Wegovy for obesity. Novo Nordisk has already filed an application for an oral version of Wegovy and also has several next-generation candidates in its obesity pipeline, like CagriSema and amycretin. CVS Caremark, a major pharmacy benefit manager ('PBM'), has signed a partnership with NVO to make Wegovy its preferred GLP-1 therapy for weight loss, effective July 1. Hims & Hers Health also signed a distribution partnership with NVO in April to offer Wegovy at a discounted price to its platform users. It remains to be seen if NVO's deals affect Zepbound's market share going forward. The Case for AbbVie AbbVie has successfully navigated the loss of exclusivity ('LOE') of its blockbuster drug, Humira, which once generated more than 50% of its total revenues. It has accomplished this by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and should support top-line growth in the next few years. Skyrizi and Rinvoq generated combined sales of $5.1 billion in the first quarter of 2025, reflecting growth of more than 65%. The drugs are seeing strong performance across all their approved indications. AbbVie expects combined sales of Skyrizi and Rinvoq to be around $24.7 billion in 2025 and more than $31 billion by 2027. The company's oncology strategy is also gaining traction, supported by increasing contributions from newer products, Elahere and Epkinly. In May, the FDA approved its antibody-drug-conjugate, Emreli (Teliso-V), for treating advanced non-squamous non-small cell lung cancer (NSCLC) AbbVie has several early/mid-stage pipeline candidates with blockbuster potential. The company expects several regulatory submissions, approvals and key data readouts in the next 12 months. The company has been on an acquisition spree in the past couple of years, which is strengthening its pipeline. It has signed several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas. It has also forayed into the lucrative obesity space through a licensing deal with Denmark-based Gubra for the latter's experimental long-acting amylin analog for obesity. However, the company faces some near-term headwinds like Humira's biosimilar erosion, increasing competitive pressure on cancer drug Imbruvica and declining sales of Juvederm fillers in the United States and China due to challenging market conditions. How Do Estimates Compare for LLY & ABBV? The Zacks Consensus Estimate for LLY's 2025 sales and EPS implies a year-over-year increase of 33.03% and 68.9%, respectively. EPS estimates for 2025 and 2026 have declined over the past 60 days. LLY Estimate Movement The Zacks Consensus Estimate for AbbVie's 2025 sales and EPS implies a year-over-year increase of 6.6% and 21.3%, respectively. The EPS estimate for 2025 has risen from $12.26 per share to $12.28 per share over the past 60 days, while that for 2026 has risen from $13.96 per share to $14.06 per share over the same timeframe. ABBV Estimate Movement Price Performance and Valuation of LLY & ABBV Year to date, while LLY's stock has risen 2.1%, AbbVie's stock has risen 6.4%. The industry has declined 0.2% in the said time frame. AbbVie looks more attractive than Lilly from a valuation standpoint. Going by the price/earnings ratio, Lilly's shares currently trade at 30.03 forward earnings, significantly higher than 14.98 for the industry. However, LLY currently trades lower than its 5-year mean of 34.54. AbbVie's shares currently trade at 14.15 forward earnings, lower than the industry. However, ABBV trades above the stock's 5-year mean of 12.40. AbbVie's dividend yield is 3.5%, while Lilly's is around 0.8%. LLY or ABBV: Which is a Better Pick? AbbVie & Lilly have a Zacks Rank #3 (Hold) each, which makes choosing one stock a difficult task. Lilly is a good stock to have in one's portfolio, considering its diversified product and pipeline portfolio and robust growth prospects despite its expensive valuation. Lilly's tremendous success with Mounjaro and Zepbound has made it the largest drugmaker with a market cap of more than $750 billion, and its stock price has crossed $800 per share. In 2025, Lilly expects to record revenues in the range of $58.0 billion to $61.0 billion, indicating an impressive 32% year-over-year growth. On the other hand, AbbVie has faced its biggest challenge — Humira's patent cliff — quite well and looks well-positioned for continued strong growth in the years ahead. AbbVie expects to return to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE, driven by its ex-Humira platform. Boosted by its new product launches, AbbVie expects to return to robust mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as it has no significant LOE event for the rest of this decade. A substantial portion of this growth is expected to be driven by robust performances from Skyrizi and Rinvoq. Overall, considering Lilly's several near-term challenges, AbbVie looks like a safer bet for short-term investors, given its price appreciation, rising estimates, cheaper valuation, stronger dividends, and solid near-term gains. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report

Japan Forward

3 hours ago

• Japan Forward

Trump World: Nice Guys Come Last, so Show Your Cards

When President Donald Trump unveiled his "reciprocal" tariffs in early April, he also invited foreign countries to offer deals that would offset the tariff damage. Japan was the first country to enter negotiations. So, there was an expectation that, being America's most important security ally in the key Indo-Pacific region, it would be treated with kid gloves and a deal would be reached fairly quickly. So far, though, little progress has been made, and "no deal" remains a real possibility. On the other hand, America's number one foe, China, was able to negotiate a significant reduction in United States tariffs in a matter of days. The reason: China has a near-monopoly on the mining and smelting of the rare earths crucial for high-tech industrial processes. The details of the China-US agreement are scarce. However, it remains the case that China can cut off the supply at any time it chooses. In the Machiavellian world of great power rivalries, Xi Jinping holds a high denomination card. He doesn't need to use it. Just brandishing it from time to time makes the point. United States Federal Reserve in Washington, DC (©Wikimedia Commons) Japan has a high-denomination card, too, but far from brandishing it, Tokyo pretends it doesn't exist. That is the $1 trillion USD of US bonds held by Japanese entities, by far the largest foreign ownership. The Trump administration is highly sensitive to action in the US bond market. Hence, the constant attacks on Federal Reserve Chairman Jerome Powell. Concerns about the level of American government debt long predate the current administration. However, Trump has consciously taken a significant risk in piling up tax breaks and spending commitments in his recent "big beautiful bill." (The one described by Elon Musk as a "disgusting abomination.") A bond market rebellion leading to higher interest rates could sink his presidency, as he must know. Before the negotiations got going, Finance Minister Katsunobu Kato made an off-the-cuff comment on Japanese TV about US bonds being a possible "card" that Japan could play. The very next day, he walked back his words, stating that Japan would never do such a thing. Presumably, he was "got at" by his officials who, naively, assumed that being cooperative would earn rewards. The episode was reminiscent of the fate of Prime Minister Ryutaro Hashimoto, one of Japan's bolder leaders. In the late 'nineties, he suggested that Japan should sell its already considerable holdings of US treasury bonds and buy gold instead. The result was a mini-tempest in global markets and a hasty denial by Hashimoto. Instead, the man who had the foresight to kickstart Japan's Big Bang in financial services was suckered again. His officials persuaded him to raise the consumption tax in the midst of a severe banking crisis, thus ending his premiership and, effectively, his political career. To his dying day, he bitterly regretted having accepted the advice of his officials. The message back then was that Japan should remain a tributary possession of the United States. Taxes on consumption were steadily increased. That continued, even under the premiership of Shinzo Abe, who did so much to overturn conventional wisdom in other areas. Japanese Finance Minister Katsunobu Kato (right) shakes hands with US Treasury Secretary Scott Bessent on April 24, 2025. (©Japan Ministry of Finance). Japan is the world's largest creditor nation. Yet, there was a constant doom-mongering chorus from the rating agencies and establishment economists. They moaned about the risks of Japan's internal debt ー which was owed by one set of Japanese to another set of Japanese. Japan has continued to run current account surpluses decade after decade. That has helped to enable American overconsumption through Japanese over-saving. No doubt, it seemed a safe and simple strategy. But the second coming of Donald Trump raises all sorts of new possibilities. Currency regimes have undergone two controlled upheavals in the last 55 years. First was President Nixon's scrapping of the gold standard in 1970. The second was the Plaza Accord to drive down the value of the US dollar against the yen and the West German mark in 1985. Interestingly, in real terms (taking account of accumulated inflation), the dollar is roughly as high as it was pre-Plaza, and the yen at the same level as it was in 1971. Are we about to experience a similar upheaval, designed to devalue the dollar? If so, it would be unlikely to be the result of a "G7" type powwow. Today's world is too chaotic for that. More likely, it would be a genuine shock, like the end of the gold standard. Already, some disturbing ideas have been floated. The proposal to coerce American allies into buying 100-year bonds at much below market interest rates is one example. Stephan Miran, Chair of the Council of Economic Advisors in the Trump administration, dreamed up that one. If inflation picked up, there could well be pressure on the Fed to keep interest rates below the level of consumer prices. As has been the case in Japan, the result would be a super-weak currency. In any of these scenarios, selling US government bonds would be a smart move. And in the current situation, nothing can be ruled out. At the very least, Japan needs to maximize its leverage by brandishing its cards and showing that it is not afraid to use them. Author: Peter Tasker Find other essays and analyses by the author on JAPAN Forward .

3 hours ago

Carney bulldozes his nation-building bill through Parliament

Agreement comes 18 months after negotiations began, according to Crown corporation. Companies appealing after Ontario decision that they unlawfully charged workers for jobs at Canadian Tire. Canada could hike tariffs on American steel and aluminum if there's no deal in 30 days. Nearly a dozen RCMP units are trying to piece together what happened to Lilly and Jack Sullivan. Other recommendations aimed at improving aviation policy, air travel access in Canada's North.